Literature DB >> 31420407

ESA Resistance May Be a Potential Confounder for Mortality among Different ESA Types.

Mototsugu Tanaka1, Kayo Shinohara2, Akiko Ono2, Mutsuhiro Ikuma2.   

Abstract

Entities:  

Keywords:  anemia; chronic kidney disease; end-stage renal disease; erythropoietin; hemodialysis

Mesh：

Substances：

Year:  2019        PMID： 31420407      PMCID： PMC6727264          DOI： 10.1681/ASN.2019060556

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  4 in total

Review 1.  Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.

Authors:  Emilee R Wilhelm-Leen; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2015-01-28       Impact factor: 8.860

2.  Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.

Authors:  Yusuke Sakaguchi; Takayuki Hamano; Atsushi Wada; Ikuto Masakane
Journal:  J Am Soc Nephrol       Date:  2019-04-23       Impact factor: 10.121

3.  Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality.

Authors:  Juan M López-Gómez; José M Portolés; Pedro Aljama
Journal:  Kidney Int Suppl       Date:  2008-12       Impact factor: 10.545

4.  Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.

Authors:  Allen R Nissenson; Suzanne K Swan; Jill S Lindberg; Steven D Soroka; Robert Beatey; Chao Wang; Nancy Picarello; Anna McDermott-Vitak; Bradley J Maroni
Journal:  Am J Kidney Dis       Date:  2002-07       Impact factor: 8.860
  4 in total
  1 in total

1.  Authors' Reply.

Authors:  Yusuke Sakaguchi; Takayuki Hamano; Atsushi Wada; Ikuto Masakane
Journal:  J Am Soc Nephrol       Date:  2019-08-16       Impact factor: 10.121
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.